The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conference covers topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.


To convene a group of researchers, physicians, and other health care professionals with a shared interest in the clinical importance and relevance of modulating the gut microbiome to revolutionize the management of infectious and chronic disease states, in which human intestinal microbiota play a critical role. Through the extensive information presented on the pathophysiologic mechanisms of intestinal microbiota, novel detection modalities to assist accurate and timely diagnosis, and therapeutic approaches to manipulating and correcting dysbiosis, participants in the 1.5 day Gut Microbiome Conference will review the most current information emerging from a critical and burgeoning field of research and clinical development.


Gastroenterologists; internists; family practitioners; physician assistants and physicians-in-training with an interest in the pathophysiology, diagnosis, and clinical management of gastrointestinal and hepatic diseases.


A considerable need exists for focused educational activities directed to physicians and other healthcare professionals who manage patients with acute and chronic gastrointestinal disorders. Mounting evidence suggests an active and complex involvement of the intestinal microbiota in gastrointestinal disorders, the etiology of which in many cases remains elusive. Patients with IBS, IBD, and celiac disease comprise a heterogeneous population, which responds variably to current standards of care. Thus, clinicians would benefit from a better appreciation of how microbial-induced inflammation and immunological reactivity may assist in identifying origins of disease, classifying patient subgroups, and individualizing effective treatment strategies.


Upon completion of this conference, participants should be better able to:

  • Understand the pathophysiologic influence of microbial metabolism as it relates to the etiology and progression of infectious and chronic gastrointestinal diseases.
  • Describe current research advances in our understanding of how dysbiosis of microbial species and induction of inflammation by functionally altered commensal bacteria interact with defective host immunoregulation.
  • Examine the role of the gut microbiome in energy harvest and fat storage and explore differences in the microbiota of obese and lean individuals, which may adversely influence metabolic parameters.
  • Discuss the evidence base for prevention of functional gastrointestinal disorders through the use of prebiotics, probiotics, and synbiotics.
  • Relate the early, postnatal composition of gut microbiota to principal metabolic functions in the adult
  • Debate the advantages and disadvantages of modulating the gut flora through dietary modification, exogenous supplementation or replacement of beneficial commensal bacteria, and effects of non-absorbable antibiotics on symptomatic improvement in a variety of GI disorders.

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the GI and Liver Association of the Americas (GALA) and The Texas Liver Institute. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.


    The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of TBD AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. A maximum of TBD contact hours may be earned for successful completion of this activity.


    All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education (ACHS), consults for Pfizer, Inc.; John Bayliss, VP, Business Development, partner is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and Focus Medical Communications staff have no relationships to disclose.


    The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity. Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.